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Abstract
The serglycin proteoglycan is expressed in most hematopoietic cells and is packaged into secretory vesicles for constitutive or regulated
secretion. We have now shown serglycin mRNA expression in undifferentiated murine embryonic stem (ES) cells and in embryoid bodies,
and synthesis and secretion in undifferentiated ES cells. Serglycin was localized to ES cell cytoplasm by immunostaining. Serglycin mRNA
is expressed in tal-1( / ) ES cells and embryoid bodies; tal-1(  / ) mice cannot produce hematopoietic cells. Thus, ES serglycin
expression is probably not associated with hematopoiesis. Serglycin expression was increased by treatment of ES cells with retinoic acid
(RA) and dibutyryl cAMP (dbcAMP). The serglycin core protein obtained from control ES culture medium after chondroitinase digestion
appears as a doublet. Only the lower Mr band is present in serglycin secreted from RA-treated and the higher Mr band in RA+ dbcAMP-
treated cells, suggesting that core protein structure is affected by differentiation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The purpose of this study was to characterize serglycin
proteoglycan synthesis in embryonic stem (ES) cells. Thus
far, proteoglycans of ES cells have not been analyzed.
Serglycin was discovered as a secretory product of rat L2
yolk sac tumor cells [1–4], which are thought to originate
from parietal endoderm [5], and is also synthesized by the
yolk sac-derived F9 cells when differentiated to visceral
endoderm by retinoic acid (RA) or to parietal endoderm by
RA and dibutyryl cAMP (dbcAMP) [6]. Serglycin is widely
expressed in hematopoietic cells [7]. Serglycin mRNA is
expressed [8,9] and the proteoglycan is synthesized by
human endothelial cells [9] and by murine mesometrial
decidua during mid-stage pregnancy [10].
The serglycin proteoglycan is unique in that it has a
central core of serine–glycine repeats, numbering 8 in
mouse and human, and 21 in rat, in which the serine
residues serve as the attachment sites for the glycosamino-
glycans (GAGs). The resultant structure involves a cluster-
ing of GAG chains that provides a conformation not found
in other proteoglycans. The length of the GAG chains varies
in a cell-specific fashion. Cell-specific serglycin structures
probably determine interactions with cell-specific secretory
granule proteins. Serglycin from most blood cells and
endothelial cells bears chondroitin sulfate GAG chains,
but some hematopoietic tumor cell lines have a small
percentage of heparan sulfate GAGs, and mucosal mast cell
serglycin is the only proteoglycan which bears heparin
GAGs [2,7,9,11–14].
Serglycin is packaged into secretory granules or vesicles.
It is either released by regulated secretory pathways, for
example, in platelets, mast cells, or neutrophils, or is
constitutively secreted, for example, from lymphocytes
and hematopoietic tumor cell lines [7,13–17], endothelial
cells [9], or uterine decidua [10], along with granule
proteins. Serglycin binds to several physiologically impor-
tant secretory granule proteins, for example, mast cell
chymases [18], cytokines and chemokines as Platelet Factor
4 and MIP-1a [12], and extracellular matrix molecules such
as collagens and fibronectin [13,19]. The intact structure of
the serglycin proteoglycan is critical for binding to the other
proteins. The intact chondroitin sulfate form of serglycin,
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but not free GAG chains isolated from the molecule, binds
effectively to fibronectin, collagen [4,13,19], and CD44
[20,21]. We have shown that Wistar–Furth rats, which have
a defect in the structure and protein content of the platelet
secretory alpha granules, synthesize a platelet serglycin with
abnormally short chondroitin sulfate chains [19]. The
importance of intact proteoglycan and GAG structure has
been borne out dramatically in vivo for the heparin sergly-
cin. Gene deletion of NDST-2, a critical sulfotransferase
which is required for synthesis of heparin, disrupts the
structure of the mast cell heparin serglycin proteoglycan.
This leads to disruption of interactions of serglycin with
granule proteins and consequently alters the structure and
function of the mast cell secretory granules [11,22].
Proteoglycans of ES cells and EBs have not been
characterized previously. Little is known about proteoglycan
synthesis during the preimplantation stages of embryogen-
esis. Syndecan 1 appears at the four-cell stage [23]. Perlecan
is expressed in Day 4 blastocysts [24,25], but expression has
not been localized to a specific cell type within the blasto-
cyst.
In contrast, considerable information is available about
proteoglycan synthesis in mid-stage to late embryos.
Numerous chondroitin sulfate, heparan sulfate and keratan
sulfate proteoglycans are synthesized in association with
cardiac, skeletal, or nervous system development. These
include syndecans 1, 2, and 3 [23,26,27], perlecan [24,
25,28], versican [29–31], decorin [32], lumican [32,33] and
neurocan [31,34–36]. Serglycin is expressed in parietal
endoderm postimplantation [1,10], but it is not known if
this occurs before implantation. We saw no evidence for
serglycin staining in blood islands of 7.5–8.5 dpc murine
embryos, and the first evidence of serglycin in blood cells
was in the fetal liver [10].
We have now found by biosynthetic studies, mRNA
expression, and immunohistochemistry that mRNA for
serglycin proteoglycan is expressed by undifferentiated ES
cells and embryoid bodies, and expression is increased by
RA in combination with dbcAMP. Serglycin is synthesized
as a chondroitin sulfate proteoglycan and secreted by ES
cells, and is localized to cytoplasm within the cells.
2. Materials and methods
2.1. Cells and cell culture conditions
ES cell lines D3 and E14.1 were kindly donated by P.
Doetschman (University of Cincinnati) and the HM-1 cell
line [37] was obtained from Dr. D.W. Melton (Edinburgh,
Scotland) [38]. The ES-D3, E14.1 and HM-1 cells had been
adapted to grow on plastic tissue culture dishes. ES tal-
1(  / ) cells were obtained from Drs. Ramesh Shivdasani
and Stuart Orkin [39]. The tal-1 (SCL) gene is a member of
the basic domain helix–loop–helix (bHLH) class of tran-
scription factors. Yolk sacs from these mice are unable to
produce hematopoietic cells in culture or in the embryo, and
the embryos die in utero [39]. The tal-1(  / ) ES cells were
cultured on mitomycin-inactivated embryonic fibroblast
feeder cells. All cells were incubated at 37 jC in the
presence of 5% CO2 and 95% humidity. All culture reagents
were from GIBCO/BRL (Grand Island, NY) except for fetal
bovine serum, which was from Hyclone (Logan, UT). All
culture media contained 100 U/ml penicillin and 100 Ag/ml
streptomycin. The culture medium was high-glucose
DMEM, 15% fetal calf serum, and monothioglycerol (1
Al/ml of culture medium). Leukemia inhibitory factor (LIF)
was prepared as supernatants from methotrexate-treated
CHO-LIF cells (donated by Genetics Institute, Cambridge,
MA), and was used at 1:1000 in the ES culture medium. The
ES cells were subcultured every 2 days. Embryoid bodies
(EB) were generated by replating single-cell suspensions in
bacterial plates with high-glucose DMEM/15% FCS with-
out LIF or monothioglycerol. EBs were harvested between 6
and 8 days of culture. They had the expected morphologic
appearance of large firm clusters of cells surrounded by
membranous material. ES cell cultures were differentiated
with dbcAMP and RA at the concentrations used for F9
teratocarcinoma cells [40]. The cells were plated in gelatin-
coated tissue culture flasks and incubated in complete ES
cell culture medium and with 10 3 M dbcAMP or 10 7 M
all-trans RA (both from Sigma, St. Louis, MO) alone, or
with both agents together. Under these conditions, the cells
formed clumps which adhered to the culture dish. Cells were
analyzed after 2–4 days of growth.
2.2. RNA extraction and analysis
RNA was extracted with Trizol (GIBCO/BRL/Life Sci-
ences) according to the directions of the manufacturer. RT-
PCR was performed as described previously [9]. Two
different primer sets were used for serglycin, both of which
spanned large introns. The forward primer for both sets was
5V-152GCTGCAAACCGAATGGCTTT and reverse primers
were 5V-466TGGTTCTGGTTGGTCTTCTG or 5V-870AATG-
CGAGTTGGGTTCCTGA, to give cDNA products of 314
(primer set A) and 718 bp (primer set B), respectively.
Primer set B encompasses exons 2 and 3. PCR for actin
was run as a parallel control with each sample. All bands
were subcloned into sequencing vectors and sequences
were obtained in the institutional automated sequencing
facility.
Northern blot analysis was performed as described pre-
viously [41]. The blots were probed with the 314-bp
serglycin PCR product described above, which was synthe-
sized by RT-PCR using mouse bone marrow cell RNA as a
template and then labeled with a-32P-dCTP (New England
Nuclear) using a random hexamer priming kit (GIBCO/
BRL). Probes for actin or glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were used as controls. Prehybrid-
ization, hybridization and washing were carried out as
described [41].
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2.3. Metabolic labeling of ES cells with 35S-sulfate
The cells were incubated with 0.1 mCi/ml 35S-sulfate
(ICN Radiochemicals, Costa Mesa, CA). The cell layers
were rinsed with culture medium to remove residual 35S-
sulfate and were solubilized in 8 M urea, 50 mM Tris–
HCl, 0.2% Triton X-100. Proteoglycans were isolated from
the cell extracts and the culture medium by DEAE-Sepha-
cel (Pharmacia, Piscataway, NJ) chromatography [16].
Aliquots were removed from the proteoglycan fractions
for liquid scintillation counting to determine total incorpo-
ration of 35S-sulfate into cell-associated and secreted
proteoglycans. The size distribution of the proteoglycans
was determined by Sepharose CL-6B (Pharmacia) gel
filtration as described previously [16]. The void volume
(Vo) was marked by blue dextran and the total column
volume (Vt) by phenol red. Chondroitinase ABC and
heparitinase II (Seikagaku, Iyamsville, MD) digestions
were performed in the presence of protease inhibitors as
described previously [16]. Chondroitinase or heparitinase
digests of the proteoglycans were passed through Sepha-
dex G-25 columns (PD-10, Pharmacia) to separate the 35S-
sulfate-labeled disaccharides from the undigested 35S-sul-
fate-labeled proteoglycans to calculate the percentage of
chondroitin sulfate in the GAGs.
2.4. Preparation of antisera against murine serglycin in
chickens
A 15-amino acid peptide YPARRARYQWVRCKP
derived from the N-terminal region of the serglycin core
protein sequence [15] was prepared at the University of
Virginia Biomolecular Research Facility (Charlottesville,
VA). The peptide was coupled to keyhole limpet hemocya-
nin (mcKLH, Pierce Chemical Company, Rockford, IL),
and injected into chickens for production of antibodies
(Cocalico, Reamstown, PA) [10]. The reactivity of the
antibody was tested by slot blotting against the uncoupled
peptide and against recombinant murine serglycin which
had been prepared in pGEX-6P2 (Pharmacia) using a full-
length cDNA which had been prepared by RT-PCR of
murine bone marrow RNA. We affinity purified the anti-
serglycin antibody using a column prepared by coupling the
peptide to epoxy-activated Sepharose 6B (Pharmacia)
according to the directions from the supplier. For the
control, crude IgY (Cocalico) was passed through the
serglycin affinity column, and fractions equivalent to those
for the specific antibody purification were used for the
control.
2.5. Western blotting
Proteoglycans were purified from the culture medium
by initial purification on Q-Sepharose (Pharmacia) and
subjected to chondroitinase ABC digestion in the presence
of protease inhibitors to remove the GAG chains from the
core protein. The digest was electrophoresed on SDS-
PAGE gels (0.75-mm-thick mini-gels, 4–20% acrylamide
gradient Ready-Gels; BioRad Laboratories, Richmond,
CA) and electrophoretically transferred to nitrocellulose.
The membrane was soaked in blocking buffer (10% non-
fat dry milk/1 /PBS/0.3% Tween-20) for 1 h. The mem-
brane was then treated with anti-serglycin antibody
(1:100), washed, and incubated with rabbit anti-chicken
alkaline phosphatase-conjugated antibody (Sigma Chemical
Co., St. Louis, MO) at 1:1000 dilution for 1 h. The
membrane was washed and then the color reaction was
carried out with Phosphatase Substrate (BCI) (Kierkegaard
and Perry Laboratories, Gaithersburg, MD). Affinity-puri-
fied pre-immune chicken IgY was the negative control.
2.6. Immunocytochemistry
Cells were grown on plastic slide chambers for 4 days in
the presence of LIF. RA and dbcAMP were added to the
cells as described above. The culture medium was removed,
medium was rinsed off with PBS, and the cells were fixed in
methanol. The cells were blocked with normal goat serum.
Slides were incubated with chicken anti-murine serglycin
antibody for 1 h, washed with PBS, incubated with bio-
tinylated goat anti-chicken IgG (Vector), and detected with
the Vectastain DAB kit using the nickel method. Affinity-
purified pre-immune chicken IgY was the negative control.
The slides were photographed with Ektachrome 64T film
(Kodak) using a Nikon microscope at total magnification of
 400 or  1000.
3. Results
3.1. Detection of serglycin mRNA expression in ES cells and
embryoid bodies
Fig. 1a (left panel) shows the RT-PCR products of
serglycin and actin in three undifferentiated ES cell lines.
The serglycin primer set A (314-bp product) was used.
Fig. 1a (right panel) shows the RT-PCR reactions in the
tal-1( / ) cells using the serglycin primer set B, the 718-
bp product which encompasses exons 2 and 3. Fig. 1b
shows the RT-PCR reactions from mRNA obtained from
embryoid bodies of the three normal ES lines and from
the tal-1( / ) cells, again using serglycin primer set B.
The identification of all putative serglycin cDNA bands
was confirmed by DNA sequencing. The RT-PCR assays
on the fetal fibroblasts were negative for serglycin expres-
sion, and thus these cells did not contribute to the
expression which we have attributed to the tal-1( / )
cells. The data suggest that serglycin synthesis occurs as
early in embryogenesis as the undifferentiated ES cell,
which is derived from the inner cell mass (ICM) of the
blastocyst, and continues through differentiation of the
embryoid bodies.
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3.2. Regulation of serglycin expression by RA and cyclic
AMP: Northern blot analysis
We investigated the effects of RA and dbcAMP, which
induce parietal or visceral endoderm differentiation in F9
teratocarcinoma cells [6], on serglycin synthesis in the ES
cells. The Northern blot analysis (Fig. 2a) shows no
increase in serglycin expression with dbcAMP alone.
Fig. 2b shows another experiment in which the control
and dbcAMP lanes were underexposed to accommodate
the heavy labeling seen in the RA/dbcAMP-treated cells.
Expression was much greater when cells were treated with
RA in the presence than in the absence of dbcAMP; the
difference is greater than is apparent from the radiolabeled
bands because the amount of RNA on the blot from the
RA-treated cells is much greater than in the other lanes.
The response of ES cells to these agents differs from that
of F9 teratocarcinoma cells (Fig. 2c) in that serglycin is
upregulated more nearly equally in F9 cells with RA alone
or RA/dbcAMP (Fig. 2c). Our results with F9 cells
confirm a previous study [6]. In contrast to the effect of
RA on the expression of serglycin in the ES and F9 cells,
neither dbcAMP nor RA alone or together increased
serglycin expression in murine mastocytoma cells (not
shown).
3.3. Analysis of proteoglycan synthesis in ES cells
Approximately 65% of the total proteoglycans synthe-
sized by the ES cells over the 2-day incubation period
were secreted to the culture medium, as determined by
total 35S-radioactivity in the proteoglycan fraction from
the DEAE-Sephacel-purified proteoglycans from the cell
extracts and culture medium. The Sepharose CL-6B
elution profiles of the proteoglycans from the ES-D3
culture media and cells are shown in Fig. 3. Identical
profiles were obtained with the HM-1 and E14.1 cell
lines (not shown). The proteoglycans from the culture
medium (top panel) eluted as a sharp peak just past the
Vo and a broad peak at Kav 0.24. (Kav is the proportion
Fig. 1. RT-PCR determination of serglycin expression in ES cells and
embryoid bodies. (a) Undifferentiated cells. (b) Six-day embryoid bodies
(EB). Primers were described in the text. (a) Left panel shows serglycin
primer set A (314 bp), and remaining figures show primer set B (718 bp).
D3, E14.1 and HM-1 refer to the three normal ES cell lines used. tal ( /  )
refers to the tal-1( / ) cells. All putative serglycin bands were confirmed
by automated sequencing. SG= serglycin, AC= actin.
Fig. 2. Effect of RA and dbcAMP on serglycin mRNA expression: Northern blot analysis. (a) ES: experiment showing no induction by dbcAMP. (b) ES: first
two lanes underexposed to enhance clarity of third and fourth lanes. RA= all-trans retinoic acid. cAMP= dibutyryl cAMP. Note that RNA loading and actin
staining are heavier in RA lane, so difference between RA and CA/RA is greater than it appears from the radioactivity. (c) F9 cells. The serglycin probe was the
32P-dCTP-labeled 314-bp PCR fragment.
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of the distance of the peak between the Vo and the Vt of
the column, where Vo = 0 and Vt = 1.) The cellular pro-
teoglycans (bottom panel) migrated as a small peak near
the Vo and the major peak at Kav 0.31. Alkaline
borohydride digestion revealed symmetrical size distribu-
tions of GAG chains within each sample, but the mean
chain length of GAGs from the secreted proteoglycans
(Kav 0.45) was shorter than that of the cell-associated
proteoglycans (Kav 0.35). Digestion of secreted proteo-
glycans with chondroitinase ABC resulted in degradation
primarily of the molecules under the Kav 0.24 peak and
the cellular molecules uniformly across the Kav 0.33
peak. These data, together with the appearance of the
serglycin core protein on Western blots after chondroiti-
nase digestion (see below), suggests that serglycin is
found within these peaks. Approximately 75% of the
proteoglycan GAG chains in the medium and half the
chains in the cells consisted of chondroitin sulfate.
Analysis of the chondroitinase and heparitinase digests
of the culture medium proteoglycans on PD-10 (Sepha-
dex G-25) columns suggested the presence of diverse
chondroitin and heparan sulfate degradation products
(Fig. 4).
The amount of proteoglycan synthesis, based on 35S-
sulfate incorporation into proteoglycans, increased four-fold
when the cells were incubated with RA plus dbcAMP, but
Fig. 3. Sepharose CL-6B gel filtration analysis of ES-D3 proteoglycans. Cells were radiolabeled with 35S-sulfate, proteoglycans were isolated as described in
the text, and samples were applied to the Sepharose CL-6B column. (a) Proteoglycans from the culture medium; (b) cell-associated proteoglycans. Kav
represents the proportion of the distance between the void volume and total volume of the column. The scale on the right in (a) refers to the chondroitin sulfate
digestion product peak to the right of the break in the X-axis.
Fig. 4. Chondroitinase and heparitinase digests of ES-D3 secreted
proteoglycans. Samples were fractionated on PD-10 columns to distinguish
undigested proteoglycan from di- and oligosaccharide digestion products.
The void volume is at fraction 5.
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the labeling profile on the Sepharose CL-6B column did not
change in any of the three normal cell lines tested (not
shown). These data suggest that treatment with RA and
dbcAMP induced a general upregulation of ES proteoglycan
synthesis.
3.4. Western blotting of chondroitinase-digested proteogly-
cans with anti-serglycin antibody
Fig. 5 shows a Western blot which demonstrates the
presence of serglycin in the culture medium of the control,
RA-treated, and RA+ dbcAMP-treated ES cells. Proteogly-
cans were eluted from Q-Sepharose with 0.7, 0.8 and 0.9
M NaCl. Parallel experiments with 35S-labeled proteogly-
cans showed that the 0.7-M NaCl fraction consisted almost
entirely of heparan sulfate proteoglycans, while the 0.8-
and 0.9-M fractions were mixtures of heparan sulfate and
chondroitin sulfate proteoglycans (not shown). The immu-
noblot of the chondroitinase-digested proteoglycans
showed core proteins of the size range expected for
serglycin in the 0.8- and 0.9-M NaCl fractions. The bands
appeared as a doublet in the control cells. Doublets are
often characteristic of serglycins. They may represent core
Fig. 5. Serglycin core protein in ES-D3 cells. Proteoglycans from culture
media were isolated by Q-Sepharose chromatography as described in the
text, digested with Chondroitinase ABC, and electrophoresed through 4–
20% polyacrylamide mini-gels (Ready-Gel) under reducing conditions.
Digestion products from the 0.7-, 0.8- and 0.9-M NaCl eluates are shown.
The blot was probed with the chicken anti-mouse serglycin as described in
the text. CON=undifferentiated cells. RA= all-trans retinoic acid-treated
cells. CA/RA=dbcAMP/RA-treated cells.
Fig. 6. Immunostaining of cultured ES cells. Incubation conditions and the immunostaining procedures are described in the text. Panels A–C: control cells;
panels D–F: cells treated with RA/dbcAMP. Panels A, B, C, D, and F were taken at a magnification of  1000, and panel E at  400. Size bars represent 50
Am in all frames.
B.P. Schick et al. / Biochimica et Biophysica Acta 1593 (2003) 259–267264
proteins with different numbers of GAG chains, such that
the number of residual hexasaccharide stubs after chon-
droitinase digestion would account for the size differences,
or they may represent proteolytic products of the core
protein. In the case of the control ES cells, the serglycin
core protein appeared as doublets in both the 0.8- and 0.9-
M NaCl eluates from Q-Sepharose, so there may be
variability in both GAG sulfation density and the size of
the processed core protein. The cells treated with RA alone
had only the lower band, and the cells treated with
RA+ dbcAMP had only the upper band, suggesting that
the different treatments affected both sulfation character-
istics and protein processing characteristics. We cannot
explain this finding. There were several faint bands of higher
molecular weight in the 0.7-M fraction. None of these bands
was seen in the undigested proteoglycans (not shown).
3.5. Immunodetection of serglycin in ES cells
Fig. 6 shows the pattern of immunostaining of cells
which grew as clusters (A and D) and as single cells (B
and E). The cells in panels A, B, C, D, and F were
photographed at  1000 and panel E at  400. The clusters
and single cells shown from each condition were from the
same slide chamber. The cells in panels A, B, D and E were
treated with anti-serglycin antibody. The cells in panels C
and F are treated with affinity-purified control IgY. Dark
staining is seen in the cytoplasmic regions of both the
control and the RA+ dbcAMP-treated cells (arrows). Other
experiments with control cells show staining also at 2 days
(not shown). The serglycin staining in both cases is primar-
ily cytoplasmic, consistent with the usual location of ser-
glycin in cytoplasmic secretory vesicles, and perinuclear, as
we have shown for endothelial cells [9] and uterine decidua
[10]. The clusters were generally much larger in the control
cultures, but the single cells adhering to the plastic were
larger in the RA+ dbcAMP-treated cells. We cannot explain
this finding.
4. Discussion
Our study has demonstrated that serglycin mRNA is
expressed in undifferentiated ES cells and in EBs, and that
the proteoglycan is synthesized and secreted by ES cells in
culture. Serglycin in ES cells bears chondroitin sulfate
chains. The cytoplasmic localization of serglycin in ES cells
suggests that this proteoglycan is present in secretory
vesicles, as is true for differentiated cells such as nucleated
blood cells and platelets. Synthesis continues throughout the
6 days of embryoid body development described in this
paper. We suggest that synthesis in the embryoid bodies is
most likely not related to hematopoiesis for the following
reasons. Although hematopoiesis begins at 6 days in the
EBs, it is only detectable by replating the cells in colony
assays, and at this stage is limited to primitive erythroid
cells [42–46]. It would be most relevant in the embryo to
cells in developing blood islands which arise from the
mesoderm at 7.5–8.5 dpc. We have found that the blood
islands do not express serglycin mRNA [10]. In contrast, the
hematopoietic cells of fetal liver express serglycin [10]. The
expression of serglycin in the tal-1( / ) ES cells and EBs
is consistent with non-hematopoietic expression of this
proteoglycan, because tal-1(  / ) mice are devoid of hem-
atopoiesis and endothelial development, and deletion of tal-
1 is embryonic lethal [39,47]. The expression of serglycin in
the EBs is most likely related to the early stages of develop-
ment of parietal endoderm. The significance of serglycin
expression in the undifferentiated ES cells is not understood,
but the possible functions are discussed below.
We have examined the effects of RA on serglycin syn-
thesis in ES cells. The upregulation of serglycin mRNA
expression in ES cells and F9 teratocarcinoma cells by RA
and dbcAMP appears to be unique. RA induces upregula-
tion of serglycin in F9 cells to the same degree with or
without dbcAMP; however, RA alone induces visceral
endoderm and RA+ dbcAMP induces parietal endoderm
differentiation [6]. The apparent requirement of dbcAMP
along with RA for maximal stimulation of serglycin mRNA
expression in the ES cells may indicate that parietal endo-
derm differentiation is preferred to visceral endoderm differ-
entiation at the stages we were evaluating. There is
considerable cell specificity regarding response to agents
which can affect serglycin synthesis. For example, dbcAMP
alone greatly upregulates serglycin synthesis in megakaryo-
blastic cell lines and HL-60 promyelocytic cells [48], but
RA has no effect (B.P. Schick, unpublished). Serglycin
mRNA expression is upregulated in megakaryoblastic cells
by phorbol-12-myristate-13 acetate (PMA) [13,14,49], but
downregulated by PMA in myeloid cell lines [48–50],
probably through a mechanism which involves cAMP
[48]. Dexamethasone and TNF-a do not affect serglycin
mRNA expression in these cells (B.P. Schick, unpublished).
In contrast, serglycin mRNA expression is upregulated by
dexamethasone in mast cells [51], and by TNF-a in human
umbilical vein endothelial cells [8]. Thus, serglycin syn-
thesis is regulated in a highly cell-specific fashion via a
variety of external stimuli. RA causes elevation of gene
expression of a number of gene products of ES cells as
assessed by microarray [52]. RA has been reported to
induce neuronal [53], cardiac myocyte [54] and adipocyte
[55] differentiation in EBs. We have seen no evidence for
serglycin in these developing structures at the E10–13 day
period [10].
We speculate here on the possible roles for serglycin in
ES cells. We hypothesize that serglycin synthesis and
secretion might be important for modulating interactions
between the ICM and trophectoderm in the blastocyst. ES
cells are derived from and maintain the same pluripotency
as the ICM [56]. The presence and proper development of
the ICM are required for trophectodermal proliferation in
preparation for implantation [57,58], and thus it is likely
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that signals which regulate trophectoderm proliferation and
function are elaborated from the ICM. Dardik and Schultz
[59] showed that the ICM secreted proteins into the
blastocoel fluid and to the culture medium. The ICM
expresses mRNA for several cytokines, and the presence
of some of the proteins has been demonstrated [60].
Coordinate secretion of serglycin bound to these proteins
could be involved in the transmission of cytokine or
growth factor signals from the ICM to the trophectoderm,
or vice versa, or to and from the uterus during implanta-
tion. These molecules include FGF4, which has been found
in ICM [61], or TGF-h which is known to be secreted
from ES cells [62]. The secreted 35S-methionine-labeled
proteins which remained at the top of the 10% polyacry-
lamide gel [59] would be consistent with the presence of
proteoglycans. We have found that the ES cells also
synthesize a heparan sulfate proteoglycan with a core
protein of size consistent with perlecan (B.P. Schick,
unpublished). Perlecan is expressed in the blastocyst
[63], but the specific cells of the blastocyst which synthe-
size it and its localization within the blastocyst after
secretion from its site of synthesis have not been identi-
fied. Gelatinases are secreted into the blastocoel space
[64], and it is possible that serglycin or other secreted
proteoglycans might be involved in their transport or
transport of other molecules involved in matrix formation
or disassembly. Another potential function for serglycin or
other proteoglycans secreted into the blastocoel might be
regulation of the osmolarity of the secretory vesicles
themselves or the osmolarity or viscosity of the fluid.
No hyaluronic acid is present in blastocysts [65], and thus
proteoglycans such as serglycin may take on importance
for maintenance of the osmolarity of the blastocoel fluid.
Future experiments will address these questions.
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